skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 64  for All Library Resources

Results 1 2 3 4 next page
Refined by: creation date: After 2018 remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review
Material Type:
Article
Add to My Research

Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review

International journal of chronic obstructive pulmonary disease, , Vol.15, p.439-460 [Peer Reviewed Journal]

2020 Iheanacho et al. ;COPYRIGHT 2020 Dove Medical Press Limited ;COPYRIGHT 2020 Dove Medical Press Limited ;2020. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 Iheanacho et al. 2020 Iheanacho et al. ;ISSN: 1178-2005 ;ISSN: 1176-9106 ;EISSN: 1178-2005 ;DOI: 10.2147/copd.s234942 ;PMID: 32161455

Full text available

2
Impact of Single Combination Inhaler versus Multiple Inhalers to Deliver the Same Medications for Patients with Asthma or COPD: A Systematic Literature Review
Material Type:
Article
Add to My Research

Impact of Single Combination Inhaler versus Multiple Inhalers to Deliver the Same Medications for Patients with Asthma or COPD: A Systematic Literature Review

International journal of chronic obstructive pulmonary disease, 2020-02, Vol.15, p.417-438 [Peer Reviewed Journal]

2020 Zhang et al. ;COPYRIGHT 2020 Dove Medical Press Limited ;COPYRIGHT 2020 Dove Medical Press Limited ;2020. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 Zhang et al. 2020 Zhang et al. ;ISSN: 1178-2005 ;ISSN: 1176-9106 ;EISSN: 1178-2005 ;DOI: 10.2147/COPD.S234823 ;PMID: 32161454

Full text available

3
Risk Factors Associated with a First Exacerbation Among Patients with COPD Classified as GOLD A and B in Routine Clinical Practice in the UK
Material Type:
Article
Add to My Research

Risk Factors Associated with a First Exacerbation Among Patients with COPD Classified as GOLD A and B in Routine Clinical Practice in the UK

International journal of chronic obstructive pulmonary disease, 2023-11, Vol.18, p.2673-2685 [Peer Reviewed Journal]

COPYRIGHT 2023 Dove Medical Press Limited ;ISSN: 1178-2005 ;EISSN: 1178-2005 ;DOI: 10.2147/COPD.S413947

Full text available

4
Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β 2 -Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England
Material Type:
Article
Add to My Research

Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β 2 -Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England

International journal of chronic obstructive pulmonary disease, 2023, Vol.18, p.231 [Peer Reviewed Journal]

2023 Requena et al. ;EISSN: 1178-2005 ;DOI: 10.2147/COPD.S389281 ;PMID: 36908830

Full text available

5
Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
Material Type:
Article
Add to My Research

Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study

Respiratory research, 2023-09, Vol.24 (1), p.229-229, Article 229 [Peer Reviewed Journal]

2023. BioMed Central Ltd., part of Springer Nature. ;COPYRIGHT 2023 BioMed Central Ltd. ;2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;BioMed Central Ltd., part of Springer Nature 2023 ;ISSN: 1465-993X ;ISSN: 1465-9921 ;EISSN: 1465-993X ;DOI: 10.1186/s12931-023-02523-1 ;PMID: 37749551

Full text available

6
Correction: Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
Material Type:
Article
Add to My Research

Correction: Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study

Respiratory research, 2024-04, Vol.25 (1), p.152-152 [Peer Reviewed Journal]

COPYRIGHT 2024 BioMed Central Ltd. ;2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2024 ;ISSN: 1465-9921 ;ISSN: 1465-993X ;EISSN: 1465-993X ;DOI: 10.1186/s12931-024-02745-x ;PMID: 38561735

Full text available

7
DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach
Material Type:
Article
Add to My Research

DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach

Advances in therapy, 2023-10, Vol.40 (10), p.4282-4297 [Peer Reviewed Journal]

The Author(s) 2023. corrected publication 2023 ;ISSN: 0741-238X ;EISSN: 1865-8652 ;DOI: 10.1007/s12325-023-02583-1

Digital Resources/Online E-Resources

8
Treatment pathways, economic burden and clinical outcomes in new users of inhaled corticosteroid/long-acting B2-agonist dual therapy with chronic obstructive pulmonary disease in a primary care setting in England: a retrospective cohort study
Material Type:
Article
Add to My Research

Treatment pathways, economic burden and clinical outcomes in new users of inhaled corticosteroid/long-acting B2-agonist dual therapy with chronic obstructive pulmonary disease in a primary care setting in England: a retrospective cohort study

BMJ open, 2024-02, Vol.14 (2), p.e072361 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2024 Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2024 ;ISSN: 2044-6055 ;EISSN: 2044-6055 ;DOI: 10.1136/bmjopen-2023-072361 ;PMID: 38326272

Full text available

9
Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England
Material Type:
Article
Add to My Research

Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England

International journal of chronic obstructive pulmonary disease, 2023-01, Vol.18, p.1431-1444 [Peer Reviewed Journal]

2023 Requena et al. ;COPYRIGHT 2023 Dove Medical Press Limited ;2023 Requena et al. 2023 Requena et al. ;ISSN: 1178-2005 ;ISSN: 1176-9106 ;EISSN: 1178-2005 ;DOI: 10.2147/COPD.S411437 ;PMID: 37465818

Full text available

10
Correction to: DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach
Material Type:
Article
Add to My Research

Correction to: DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach

Advances in therapy, 2023-10, Vol.40 (10), p.4689-4690 [Peer Reviewed Journal]

Springer Healthcare Ltd., part of Springer Nature 2023 ;ISSN: 0741-238X ;EISSN: 1865-8652 ;DOI: 10.1007/s12325-023-02613-y

Digital Resources/Online E-Resources

11
INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice
Material Type:
Article
Add to My Research

INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice

ERJ open research, 2021-04, Vol.7 (2), p.950 [Peer Reviewed Journal]

Copyright ©The authors 2021. ;Copyright ©The authors 2021 2021 ;ISSN: 2312-0541 ;EISSN: 2312-0541 ;DOI: 10.1183/23120541.00950-2020 ;PMID: 34109236

Full text available

12
Burden of Disease in Patients with Mild or Mild-to-Moderate Chronic Obstructive Pulmonary Disease (Global Initiative for Chronic Obstructive Lung Disease Group A or B): A Systematic Literature Review
Material Type:
Article
Add to My Research

Burden of Disease in Patients with Mild or Mild-to-Moderate Chronic Obstructive Pulmonary Disease (Global Initiative for Chronic Obstructive Lung Disease Group A or B): A Systematic Literature Review

International journal of chronic obstructive pulmonary disease, 2023-05, Vol.18, p.719-731 [Peer Reviewed Journal]

2023 Czira et al. ;COPYRIGHT 2023 Dove Medical Press Limited ;2023 Czira et al. 2023 Czira et al. ;ISSN: 1178-2005 ;ISSN: 1176-9106 ;EISSN: 1178-2005 ;DOI: 10.2147/COPD.S394325 ;PMID: 37151760

Full text available

13
Benefit of Prompt Vs Delayed Initiation of Triple Therapy Following an Exacerbation in Patients with COPD in Japan: A Retrospective Cohort Study
Material Type:
Article
Add to My Research

Benefit of Prompt Vs Delayed Initiation of Triple Therapy Following an Exacerbation in Patients with COPD in Japan: A Retrospective Cohort Study

International journal of chronic obstructive pulmonary disease, 2023-01, Vol.18, p.2933-2953 [Peer Reviewed Journal]

2023 Czira et al. ;COPYRIGHT 2023 Dove Medical Press Limited ;2023 Czira et al. 2023 Czira et al. ;ISSN: 1178-2005 ;ISSN: 1176-9106 ;EISSN: 1178-2005 ;DOI: 10.2147/COPD.S419119 ;PMID: 38089540

Full text available

14
Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis
Material Type:
Article
Add to My Research

Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis

Advances in therapy, 2022-09, Vol.39 (9), p.3957-3978 [Peer Reviewed Journal]

The Author(s) 2022 ;ISSN: 0741-238X ;EISSN: 1865-8652 ;DOI: 10.1007/s12325-022-02231-0

Digital Resources/Online E-Resources

15
Correction to: A tutorial on pilot studies: the what, why and how
Material Type:
Article
Add to My Research

Correction to: A tutorial on pilot studies: the what, why and how

BMC medical research methodology, 2023-03, Vol.23 (1), p.59-59, Article 59 [Peer Reviewed Journal]

COPYRIGHT 2023 BioMed Central Ltd. ;2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2023 ;ISSN: 1471-2288 ;EISSN: 1471-2288 ;DOI: 10.1186/s12874-023-01880-1 ;PMID: 36927764

Full text available

16
Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK
Material Type:
Article
Add to My Research

Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK

ERJ open research, 2021-01, Vol.7 (1), p.480 [Peer Reviewed Journal]

Copyright ©ERS 2021. ;Copyright ©ERS 2021 2021 ;ISSN: 2312-0541 ;EISSN: 2312-0541 ;DOI: 10.1183/23120541.00480-2020 ;PMID: 33778055

Full text available

17
Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis
Material Type:
Article
Add to My Research

Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis

Advances in therapy, 2022-11, Vol.39 (11), p.4961-5010 [Peer Reviewed Journal]

The Author(s) 2022. corrected publication 2022 ;ISSN: 0741-238X ;EISSN: 1865-8652 ;DOI: 10.1007/s12325-022-02234-x

Digital Resources/Online E-Resources

18
Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK
Material Type:
Article
Add to My Research

Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK

International journal of chronic obstructive pulmonary disease, 2023-01, Vol.18, p.1815-1825 [Peer Reviewed Journal]

COPYRIGHT 2023 Dove Medical Press Limited ;2023 Kendall et al. 2023 Kendall et al. ;ISSN: 1178-2005 ;ISSN: 1176-9106 ;EISSN: 1178-2005 ;DOI: 10.2147/COPD.S400707

Full text available

19
Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany
Material Type:
Article
Add to My Research

Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany

International journal of chronic obstructive pulmonary disease, 2024-01, Vol.19, p.945-956 [Peer Reviewed Journal]

2024 Beeh et al. ;COPYRIGHT 2024 Dove Medical Press Limited ;2024 Beeh et al. 2024 Beeh et al. ;ISSN: 1178-2005 ;ISSN: 1176-9106 ;EISSN: 1178-2005 ;DOI: 10.2147/COPD.S431291 ;PMID: 38646606

Full text available

20
A Response to: Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis”
Material Type:
Article
Add to My Research

A Response to: Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis”

Advances in therapy, 2023-05, Vol.40 (5), p.2556-2561 [Peer Reviewed Journal]

The Author(s) 2023 ;ISSN: 0741-238X ;EISSN: 1865-8652 ;DOI: 10.1007/s12325-023-02495-0

Digital Resources/Online E-Resources

Results 1 - 20 of 64  for All Library Resources

Results 1 2 3 4 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
  1. Before 2019  (1)
  2. 2019 To 2019  (7)
  3. 2020 To 2020  (5)
  4. 2021 To 2022  (28)
  5. After 2022  (24)
  6. More options open sub menu

Searching Remote Databases, Please Wait